EXACENT To Provide IT VIirtualization To HybridChart

EXACENT To Provide IT VIirtualization To HybridChart

Newly Founded Medical IT Company Launches into EXACENT's Virtualized Environment

Scottsdale, Arizona (PRWEB) February 19, 2009 -- EXACENT, the leading enterprise grade - on demand virtual data center (http://www.exacent.com/), is pleased to announce HybridChart as a new express virtual server customer.

HybridChart, a Scottsdale based company, has developed innovative and user-friendly products for medical practices of all specilities. An alternative to EMR, HybridChart manages hospital rounding, medical transcription and office communication without the need for large capital investment or the disruption to individual practice styles.

Every customized version of HybridChart has the ability to improve efficiency of daily operations and reduce practice overhead. Selective digitization of medical information provides the benefits of instant access to information, without taking on any of the downsides of complete electronic conversion. Wherever there is an internet connection, secure and HIPAA-compliant access to all crucial patient data is available.

HybridChart utilizes EXACENT as their turnkey virtual data center (http://www.exacent.com/) solution where all their information will be stored and available for access 24/7/365 via the Internet. EXACENT's services will allow HybridChart to increase their performance, reliability, security, scalability, as well as support leveraging best of class infrastructure and virtualization. This combination of technology allows HybridChart to "go green" by utilizing less hardware and less space for their virtual data center (http://www.exacent.com/) needs. In addition, as HybridChart continues to expand they have the ability to dynamically and effortlessly grow their infrastructure to match their customers' needs.

"By utilizing EXACENT virtualization, HybridChart will now have the same access to the data center performance, reliability, security, scalability and support as a Fortune 100 company," said David Shepard, General Manager of EXACENT. "I am pleased to be working with such a great technology forward company."

"EXACENT provides the security and reliability we need with regards to sensitive patient information," said Dr. Gregory Sanders, HybridChart CEO. "The degree of service and support we have received is unprecedented in this industry."

EXACENT will provide HybridChart with always on, secure, data grade power and network which is guaranteed with a 100 percent uptime Service Level Agreement. EXACENT resides in i/o Data Centers Phoenix Colocation (http://www.iodatacenters.com/data-centers/arizona/phoenix-data-center.aspx) Facility, a physically secure, SAS 70 Type II certified data center. EXACENT also adheres to PCI DSS (Payment Card Industry Data Security Standard) best practices to secure web property, intellectual property and payment account data for its clients.     

About EXACENT

Scottsdale-based EXACENT is the premier global provider of on-demand enterprise grade infrastructure that is secure, scalable, efficient, redundant and highly available. Its offerings allow organizations to eliminate capital expenditures, infrastructure management and provide companies with the best infrastructure available. EXACENT is located in i/o Data Centers (http://www.iodatacenters.com), an industry leader in delivering the highest quality, fully scalable and completely reliable data center and Phoenix colocation (http://www.iodatacenters.com/data-centers/arizona/phoenix-data-center.aspx) solutions with 100 percent uptime. For more information, go to www.exacent.com.

About HybridChart

HybridChart software was developed by Gregory P. Sanders, MD, FACC - a practicing, Harvard-trained, Board-certified cardiologist. Dr. Sanders began his career in software development long before entering medical training. After years of clinical practice and frustration with corporate solutions to the electronic needs of the medical community, Dr. Sanders set out to provide a more realistic and relevant electronic environment. HybridChart has partnered with MedSoft, a full-service company, providing product implementation, training and customer service. HybridChart, commercially ready since November 2008, is available to practices of any specialty or setting. For more information, go to www.HybridChart.com.

###

Contact Information Sarah Slade

Exacent

http://www.exacent.com

866.282.5451

Gregory Sanders MD

HybridChart

http://www.hybridchart.com

480.329.0914

Toxic Element Research Foundation Announces Its Latest Worldwide Educational Programs for Health Professionals and Patients

Toxic Element Research Foundation Announces Its Latest Worldwide Educational Programs for Health Professionals and Patients

Toxic Elements Research Foundation (TERF), a non profit research foundation, announces its series of dental related health care reports under the title of 'Elements of Disease.'

Colorado Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation (TERF), a non profit research foundation, announces its series of dental related health care reports under the title of 'Elements of Disease.' Toxicity, or the inadvertent poisoning of our population, is the focal point of the Toxic Element Research Foundation. For the past thirty years, TERF has funded a wide variety of research to discover the connection between dental materials and health. Its primary focus was its research on Mercury containing dental amalgam (silver) fillings and the dangers associated with it. The FDA has finally admitted many of these dangers. TERF has turned its attention to other dental materials and procedures, and is now releasing the results of this highly controversial research to the news media and general public.

This first series of reports identifies various factions of blood tests that demonstrate extremely unhealthy aspects of not only common silver mercury fillings, but introduces the role of bacterial toxins from root canals, dental implants and cavitations. A surprising expose is presented on 'cavitations', or defects in the bone where wisdom teeth were removed. Through the use of sophisticated DNA technology, identification of the especially damaging anaerobic bacteria (those who live in the absence of oxygen) that are found in root canals and cavitations has shed new light on the potential cause and advanced treatment for diseases thought to be incurable. This research confirms data discovered and presented to the American Dental Association over ninety years ago.

Examples of the diseases that have been associated with the bacterium discovered hidden within dental procedures are MS, ALS, AD, leukemia and diabetes. With proper dental treatment and recognition of these sources of toxins and their eradication, many patients can be improved, and TERF believes most could have been avoided entirely. New generations will not have these new diseases to be concerned about IF research institutions can be encouraged to explore these newly discovered avenues of their cause.

Results and correlations are provided free of charge in order to stimulate investigative type of reporters to assist the Toxic Element Research Foundation in generating awareness in the public. TERF has created a media outreach program where media writers can visit the web site - www.terftalks.com - and e-mail their choice of two topics in addition to the basic report up on root canals, the incubators. Other topics include: cavitations, the caverns of deceit; dental implants, the invitation for Alzheimer's; cholesterol, the giver of life; chronic fatigue, complexity encompassed; sodium and potassium, the butlers; albumin, the primary detoxifier; porphyrins, the origin of all energy; methyl mercury on the red cell, the biomarker of recovery; and white blood cells, our primary defense against autoimmune diseases.

About Toxic Elements Research Foundation

TERF, a non-profit research foundation, is dedicated to stimulating interest in the research community as well as informing the public to become aware of potential problems associated with dental materials and procedures. Informed consent of potential problems makes for better informed decisions by the patient - especially where health is at risk.

###

Contact Information Jamie Tolle

Toxic Element Research Foundation

http://www.terftalks.com

719-262-2978

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###

Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146